SoVote

Decentralized Democracy

House Hansard - 320

44th Parl. 1st Sess.
May 29, 2024 02:00PM
Context: House Hansard - 320 - May/29/24
Mr. Gérard Deltell
  • May/29/24 9:22:30 p.m.
  • Watch
Mr. Speaker, are Canadians right to worry that the government might apply this pilot project, which has cost the lives of more than 2,500 people, outside British Columbia?
29 words
  • Hear!
  • Rabble!
  • star_border
Context: House Hansard - 320 - May/29/24
Mr. Mike Morrice
  • May/29/24 11:08:41 p.m.
  • Watch
Madam Chair, I am encouraged to hear that on both fronts. I appreciate that. I would like to tell the minister about another constituent of mine, Noor Ayesha. Noor is battling an incurable rare cancer. For it, she requires an oral drug. The name is Pemazyre. It has been approved by Health Canada but is not recommended by the Canadian drug agency for public coverage. Noor's oncologist recommends that she take this drug to help her live longer, but it costs $800 U.S. per tablet and has to be taken daily. It is a cost of over $15,000 U.S. per month. Here is what Dr. Jennifer Knox, a medical oncologist at the Princess Margaret Cancer Centre and professor of medicine at the University of Toronto, had to say about Pemazyre: “this drug represents real progress, a key scientific and clinical advancement.” Noor's family has had to turn to starting a GoFundMe to help her fight cancer and live longer because the Canadian drug agency has not recommended Pemazyre for coverage. What steps is the government taking to address this gap between Health Canada's approval of rare cancer drugs and the CDA's recommendations for public coverage in order to ensure that patients like Noor can access the treatment they need without prohibitive costs?
221 words
  • Hear!
  • Rabble!
  • star_border